FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model

Islets

Volumn 2, Issue 4, 2010, Pages 247-251

  Uonaga, Taeko ^a   Toyoda, Kentaro ^a   Okitsu, Teru ^b   Zhuang, Xiaotong ^a   Yamane, Shunsuke ^a   Uemoto, Shinji ^a   Inagaki, Nobuya ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

cell load; Apoptosis; Cytoprotection; Diabetes mellitus; Fibroblast growth factor 21; Insulin sensitivity; Islet transplantation

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; ENGRAFTMENT; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; ISOGRAFT; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; STREPTOZOCIN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, ISOGENEIC;

EID: 77957028948     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.2.4.12402     Document Type: Article

References (30)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2:3005.
2. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-49.
3. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16:179-86.
4. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-78. (Pubitemid 40616114)
5. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20:563-9.
6. Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse betacells leads to diabetes. Nature 2000; 408:864-8.
7. Revest JM, Spencer-Dene B, Kerr K, De Moerlooze L, Rosewell I, Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1 or Bmp4. Dev Biol 2001; 231:47-62. (Pubitemid 32198386)
8. Celli G, LaRochelle WJ, Mackem S, Sharp R, Merlino G. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 1998; 17:1642-55.
9. Elghazi L, Cras-Meneur C, Czernichow P, Scharfmann R. Role for FGFR2IIIb-mediated signals in controlling pancreatic endocrine progenitor cell proliferation. Proc Natl Acad Sci USA 2002; 99:3884-9. (Pubitemid 34252200)
10. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492:203-6.
11. Itoh N. The Fgf families in humans, mice and zebrafish: their evolutional processes and roles in development, metabolism and disease. Biol Pharm Bull 2007; 30:1819-25. (Pubitemid 47607758)
12. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282:26687-95.
13. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007; 104:7432-7.
14. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115:1627-35.
15. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55:2470-8.
16. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148:774-81.
17. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-8.
18. Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med 2007; 356:2754-5. (Pubitemid 47001066)
19. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol 2005; 77:587-97.
20. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-9.
21. Yonekawa Y, Okitsu T, Wake K, Iwanaga Y, Noguchi H, Nagata H, et al. A new mouse model for intraportal islet transplantation with limited hepatic lobe as a graft site. Transplantation 2006; 82:712-5.
22. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP. Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocinadministered baboons. Diabetes 1991; 40:673-9.
23. Xu J, Lloid DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58:250-9.
24. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, et al. Acute glucose-lowering and insulin- sensitizing action of FGF21 in insulin resistant mouse models - Association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009; 297: 1105-14.
25. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002; 51:66-72. (Pubitemid 34517981)
26. Merino JF, Nacher V, Raurell M, Aranda O, Soler J, Montanya E. Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta-cell mass and function. Diabetologia 1997; 40:1004-10.
27. King A, Lock J, Xu G, Bonner-Weir S, Weir GC. Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 2005; 48:2074-9. (Pubitemid 41416919)
28. Toyoda K, Okitsu T, Yamane S, Uonaga T, Liu X, Harada N, et al. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun 2008; 367:793-8.
29. Contreras JL, Eckstein C, Smyth CA, Bilbao G, Vilatoba M, Ringland SE, et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation and islet cell death. Diabetes 2004; 53:2804-14.
30. Huang X, Yu C, Jin C, Yang C, Xie R, Cao D, et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006; 45:934-42.